### ► verily viewpoint site CTMS

# Seamless integrations with EHRs

With clinical trials increasing in complexity, the need for systems integration has never been more important. Verily Viewpoint Site CTMS is built on a philosophy of enabling interoperability across the many systems used for study execution, via a portfolio of APIs and third party integrations.



Verily Viewpoint Site CTMS communicates with most EHRs to both send and receive data. We offer three levels of integration: patient information, study and subject information, and billing calendar integration. These features enable a range of benefits for your research team and organization at-large:

### Unlock operational efficiency

Separate systems require staff to manually enter duplicate information, leading to wasted time and potential errors in transcription. With CTMS and EHR integration, staff can spend less time entering duplicate data, while ensuring consistency of data between systems.

### Inform patient safety outcomes

If a patient visits your hospital for an emergency health issue, it is important for the medical team to be informed that the patient is currently enrolled in a trial. Viewpoint Site CTMS communicates with your EHR and flags the patient as a research participant.

## Streamline billing compliance

Separate systems make it difficult to communicate and correctly route charges, leading to errors in clinical research billing and, subsequently, to billing compliance issues. With Viewpoint Site CTMS integration, billing details are pushed to your EHR.

#### Figure 1: Example of Viewpoint Site CTMS's user-friendly EHR integration

| Profile Summary  | Analysis         |                                |   |                   | Sen               | d Billing Codes to Epic |
|--|------------------|--------------------------------|---|-------------------|-------------------|-------------------------|
| GRID VIEW  |                  | PROTOCOL                       | ountable / Not Accou<br>Routine Care INV Invo |                   |                   |                         |
| COST CHARGE WITH OH<br>ARM/EVENT:<br>ARM Interferon beta-1a SQ injection + rem • |                  | TREATMENT                      | TREATMENT                                     | FOLLOW-UP         | FOLLOW-UP         | FOLLOW-UP               |
|  |                  | Baseline                       | Study Interventio                             | Follow-up Visit 1 | Follow-up Visit 2 | Follow-up Visit 2       |
|  |                  | CHARGE<br>\$0.00               | CHARGE<br>\$0.00<br>PAY                       | CHARGE<br>\$0.00  | CHARGE<br>\$0.00  | CHARGE<br>\$0.00        |
| PROTOCOL ACTIVITIES (17)   |                  |                                |   |                   |                   |                         |
| Administration of investiga  | CHARGE<br>\$0.00 | CHARGE<br>\$0.00<br>RC INV PAY | CHARGE<br>\$0.00<br>RC INV PAY                |                   |                   |                         |
| Randomization  | CHARGE<br>\$0.00 | CHARGE<br>\$0.00<br>RC INV PAY |   |                   |                   |                         |

#### On our Roadmap: Surface potential participants directly in CTMS with EHR patient matching

Verily Viewpoint's mission is to accelerate research through innovative technology and AI, with a suite of integrated solutions across the clinical trials ecosystem. We're building AI to comb through EHR records and identify patient matches directly within Site CTMS, freeing coordinator time, increasing enrollment, and eliminating the need for a fragmented recruitment solution.

#### Viewpoint Site CTMS integrates with many of the largest EHRs in the market <sup>1</sup>



#### Learn more about Verily Viewpoint Site CTMS

Our team of clinical research experts is available to discuss how Viewpoint Site CTMS's EHR integrations can improve operational efficiency, patient safety, and billing compliance for your organization. To get more information or schedule a demo, please reach out:

verily.com/site-ctms-request

1 - Trademarks, logos and brand names are the property of their respective owners and do not constitute or imply endorsement.